Vera Therapeutics (VERA) Stock Forecast & Price Target
Score
Vera Therapeutics, Inc. price target
| VERA | |
|---|---|
| Low | $34.00 |
| Average | $80.89 |
| High | $125.00 |
| Upside vs current price | +187.9% |
The average target of $80.89 is +187.9% versus the current VERA price of $28.10.
Vera Therapeutics, Inc. analyst ratings
| Rating | Analysts |
|---|---|
| Strong buy | 1 |
| Buy | 12 |
| Hold | 2 |
| Sell | 0 |
| Strong sell | 0 |
| Consensus | Buy |
15 analysts cover VERA.
Vera Therapeutics, Inc. EPS and revenue estimates
Published annual figures for VERA on this page are 2026 EPS $-6.25, 2027 EPS $-4.27. Coverage under three analysts is omitted.
| Fiscal year | EPS estimate | Revenue estimate |
|---|---|---|
| 2026 | $-6.25 | $23.14M |
| 2027 | $-4.27 | $230.33M |
Is Vera Therapeutics, Inc. a buy or sell?
Of the 15 analysts covering Vera Therapeutics, Inc., 13 rate it a buy (1 strong buy and 12 buy), 2 rate it a hold, and 0 rate it a sell (0 sell and 0 strong sell).
The VERA consensus label is Buy, beside 13 buy-side ratings and 0 sell-side ratings.
The average target of $80.89 implies +187.9% versus the current price of $28.10.
The VERA rating block is 15 published views with a Buy label. It does not tell you whether to buy or sell.
Reading the Vera Therapeutics, Inc. forecast
A wide spread is the story on VERA. Targets run from $34.00 to $125.00, with $80.89 as the average.
The gap from the $28.10 price to the VERA average is +187.9%.
The VERA rating mix is lopsided rather than split: 13 of 15 analysts are on the buy side, 2 are at hold, and 0 are on the sell side, and the published consensus is Buy.
The recent VERA average ($34.00) is under the quarterly figure ($59.00).
the Vera Therapeutics, Inc. is followed by 15 analysts, so the range matters more than any one target.
Vera Therapeutics, Inc. forecast questions
What is the VERA price target?
The published range for VERA is $34.00 to $125.00, with an average of $80.89. That average is +187.9% versus the current price of $28.10.
Is Vera Therapeutics, Inc. a buy or sell?
Of the 15 analysts covering Vera Therapeutics, Inc., 13 rate it a buy, 2 rate it a hold, and 0 rate it a sell. The consensus is Buy, leaving VERA at 13 buy ratings, 2 holds, and 0 sells.
What is the EPS estimate for Vera Therapeutics, Inc.?
Analyst EPS estimates for Vera Therapeutics, Inc.: 2026 $-6.25, 2027 $-4.27.
What is the revenue estimate for Vera Therapeutics, Inc.?
Analyst revenue estimates for Vera Therapeutics, Inc.: 2026 $23.14M, 2027 $230.33M.
How many analysts cover VERA?
15 analysts cover VERA. Their consensus on VERA is Buy, across those 15.